Monday, March 23, 2020 2:29:49 PM
New York plans to start administering a pair of untested treatments to seriously ill coronavirus patients on a “compassionate care” basis, Gov. Cuomo said Monday.
“On the drug therapy, Tuesday we’re going to start the hydroxychloroquine with these Zithromax, that’s the drug combination that the president has been talking about,” Cuomo said during a news conference in Albany.
Cuomo said the Food and Drug Administration had also given the state permission to “proceed with an experimental drug” that “takes the plasma from a person who has been infected with the virus, processes the plasma and injects the antibodies into a person who is sick.”
“And there have been tests that show when a person is injected with the antibodies that then stimulates and promotes the immune system against that disease,” he said.
“We all believe thousands and thousands of people have had the virus and self resolved,” he said.
Cuomo also said experts in New York were developing “a serological drug, where you Cuomo also said experts in New York were developing “a serological drug, where you
test the antibodies of a person and see if they have the virus already.”
“If you knew that, you would know who is now immune to the virus and who you could send back to work, etc., so we’re also working on that.”
President Trump tweeted Saturday that the combination of hydroxychloroquine — an anti-malaria drug sold under the brand name Plaquenil — and Zithromax, the brand name for the antibiotic azithromycin, could be “one of the biggest game-changers in the history of medicine.”
Results of a small French study published last week showed that five of six people with the coronavirus who were treated with the two-drug cocktail tested negative on Day Three, and all tested negative on Day Six.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infection Diseases, cautioned Saturday that the combination of drugs hadn’t been proven to work in clinical trials.
“It’s only a trial, it’s a trial for people who are in serious condition, but the New York State Department of Health has been working on this with some of New York’s best health care agencies and we think it shows promise and we’re going to be starting that this week.”
Recent AMRX News
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine • Business Wire • 04/16/2024 12:00:00 PM
- Amneal to Report First Quarter 2024 Results on May 3, 2024 • Business Wire • 04/10/2024 12:00:00 PM
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 • Business Wire • 03/28/2024 08:05:00 PM
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension • Business Wire • 03/25/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/22/2024 12:01:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/22/2024 12:01:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:40:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:39:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:54:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:35:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 11:13:05 AM
- Amneal Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/01/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:25:51 PM
- Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 • Business Wire • 02/27/2024 01:00:00 PM
- Amneal to Participate at Upcoming Investor Conference • Business Wire • 02/13/2024 01:00:00 PM
- Amneal Announces Complete Response Resubmission for IPX203 New Drug Application • GlobeNewswire Inc. • 02/08/2024 09:05:00 PM
- Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 • Business Wire • 01/31/2024 09:05:00 PM
- Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension • Business Wire • 01/10/2024 01:00:00 PM
- Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023 • Business Wire • 01/04/2024 09:05:00 PM
- Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 12/26/2023 09:10:26 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 12/26/2023 09:05:25 PM
- Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/21/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:15:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/15/2023 09:06:54 PM
- Amneal Announces Move to Nasdaq • Business Wire • 12/15/2023 09:05:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM